News

A study from the Netherlands has found a range of minimum serum levels of adalimumab that are associated with a good clinical response in rheumatoid arthritis. As in other studies, adding methotrexate helps.

New in the non-rheumatology journals: Among osteoarthritis patients in the UK, 10-year survival rates were doubled after metal-on-metal (MoM) hip resurfacing, compared with other types of hip replacement.

Why are gout patients seeking treatment from their healthcare providers at three times the rate they were in the later 20th century? Researchers suggest that better disease awareness and an aging population may hold the answers.

ACR2013: Joints erode in systemic lupus erythematosus and primary Sjӧgren’s Syndrome. But French researchers say their MRI studies don't justify classing them as erosive disorders like rheumatoid arthritis.

ACR2013: As well as neonatal lupus and heart block, new research suggests that children born to women with lupus may face higher risks for autism and attention deficit hyperactivity disorder.

This 6-year-old boy presents to the ER with a 2-day history of increasing pain and swelling in his right ankle. On the day of his arrival, he also developed the rash pictured here. The patient denies any other symptoms aside from his ankle and knee pain. His chest X-ray, vital signs, complete blood count (CBC), and basic chemistry panel were normal, though urinalysis showed a trace of blood.

ACR 2013: Debates about drug costs in rheumatoid arthritis dominated discussions at ACR this year, and one session was formally billed a debate. Will less-costly triple therapy someday be mandated for early RA?

Reports in a pediatric ophthalmology journal reveal risk factors and best treatments for refractory/recurrent uveitis in JIA.

ACR2013: Apremilast, a new kind of anti-inflammatory, proved significantly better than placebo against psoriatic arthritis after 52 weeks. Adverse effects were short-lived. Results for ustekinumab also held up after a year.

Biomarkers in Vasculitis

By

An intense search is underway for better ways to support treatment decisions in the vasculitides. Here are the most promising candidate biomarkers for identifying active disease and predicting relapse.